Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Asset disposition
Appointed CFO
Quarterly results
Appointed director
CC transcript
CELGENE CORP (CELG) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/22/2019 8-K Completion of Acquisition or Disposition of Assets, Material Modifications to Rights of Security Holders, Financial Statement...
11/20/2019 8-K Resignation/termination of a director
Docs: "ARTICLE ONE The name of the corporation is Celgene Corporation . ARTICLE TWO The address of the Corporation’ s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company. ARTICLE THREE The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware. ARTICLE FOUR The total number of shares which the Corporation shall have the authority to issue is One Thousand shares, all of which shall be shares of Common Stock, with a par value of $0.01 per share. ARTICLE FIVE The directors shall have the power to adopt, amend or repeal By...",
"BYLAWS OF",
"ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT",
"CELGENE Announces plans to transfer listing of Celgene’ s Contingent value rights following Closing of Acquisition by Bristol-Myers Squibb"
10/31/2019 8-K Quarterly results
08/26/2019 8-K Acquisition/merger/asset purchase announced
Docs: "Asset Purchase Agreement dated August 25, 2019, by and between Celgene Corporation, as seller, and Amgen Inc., as purchaser"
07/30/2019 8-K Quarterly results
Docs: "CELGENE REPORTS SECOND QUARTER 2019 OPERATING AND FINANCIAL RESULTS"
04/25/2019 8-K Quarterly results
Docs: "CELGENE REPORTS FIRST QUARTER 2019 OPERATING AND FINANCIAL RESULTS"
04/12/2019 8-K Quarterly results
04/04/2019 8-K Other Events
03/29/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "CELGENE SETTLES U.S. REVLIMID ® PATENT LITIGATION WITH ALVOGEN"
03/26/2019 8-K Other Events
03/08/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Notice to American Stock Transfer & Trust Company, LLC"
01/31/2019 8-K Quarterly results
01/07/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "CELGENE CORPORATION ANNOUNCES 2019 FINANCIAL GUIDANCE AND KEY MILESTONES"
01/04/2019 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Agreement and Plan of Merger by and among Bristol-Myers Squibb Company, Burgundy Merger Sub, Inc. and Celgene Corporation, dated as of January 2, 2019.†",
"Form of Contingent Value Rights Agreement by and between Bristol-Myers Squibb Company and [Trustee]",
"Celgene Corporation Executive Severance Plan"
01/03/2019 8-K Investor presentation
Docs: "Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company",
"Joint investor presentation"
11/02/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Offer Letter"
10/25/2018 8-K Quarterly results
Docs: "CELGENE REPORTS THIRD QUARTER 2018 OPERATING AND FINANCIAL RESULTS"
07/26/2018 8-K Quarterly results
Docs: "CELGENE REPORTS SECOND QUARTER 2018 OPERATING AND FINANCIAL RESULTS"
07/09/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "CELGENE AND ACCELERON ANNOUNCE LUSPATERCEPT ACHIEVED PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PHASE III ‘BELIEVE’ study in ADULTS with transfusion-dependent beta-thalassemia"
07/05/2018 8-K Other Events
06/28/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "CELGENE AND ACCELERON ANNOUNCE luspatercept achieved primary and key secondary endpointS IN PHASE III ‘medalist’ study in Patients with low-to-Intermediate risk myelodysplastic syndromes"
06/19/2018 8-K Quarterly results
06/13/2018 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Amended and Restated By-Laws of Celgene Corporation BY-LAWS of CELGENE CORPORATION"
06/01/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Offer Letter",
"CELGENE CORPORATION ANNOUNCES HIRING OF DAVID V. ELKINS AS EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER AND APPOINTMENT OF PETER N. KELLOGG TO EXECUTIVE VICE PRESIDENT, CHIEF CORPORATE STRATEGY OFFICER"
05/31/2018 8-K Regulation FD Disclosure
05/24/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "CELGENE CORPORATION ANNOUNCES ADDITIONAL $3 BILLION SHARE REPURCHASE AUTHORIZATION AND PLANS TO EXECUTE A $2 BILLION ACCELERATED SHARE REPURCHASE PROGRAM"
05/04/2018 8-K Quarterly results
Docs: "CELGENE REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS"
04/30/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Amended and Restated Credit Agreement"
04/19/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CELGENE CORPORATION ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS"
04/02/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CELGENE CORPORATION ANNOUNCES DEPARTURE OF PRESIDENT AND CHIEF OPERATING OFFICER SCOTT A. SMITH"
03/06/2018 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
Docs: "CELGENE COMPLETES ACQUISITION OF JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY"
02/27/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Celgene PROVIDES Regulatory update on Ozanimod for the Treatment of RELAPSING Multiple Sclerosis"
02/20/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Indenture, relating to the 2.875% Senior Notes due 2021, the 3.250% Senior Notes due 2023, the 3.900% Senior Notes due 2028 and the 4.550% Senior Notes due 2048 between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee",
"Form of 2.875% Senior Note due 2021",
"Form of 3.250% Senior Note due 2023",
"Form of 3.900% Senior Note due 2028",
"Form of 4.550% Senior Note due 2048",
"Opinion of Proskauer Rose LLP"
02/15/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CELGENE CORPORATION ELECTS JOHN WEILAND TO ITS BOARD OF DIRECTORS"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy